The “route to quit” model, which indicates the contribution of different ways of quitting to overall rates of smoking cessation. #: in most cases nicotine.

Slides:

Advertisements

Similar presentations

Latest trends on smoking in England from the Smoking Toolkit Study Robert West Jamie Brown Last updated: 17th June 2013

Advertisements

Latest trends on smoking in England from the Smoking Toolkit Study

Quit rate (7-day point prevalence) for long-term nicotine replacement therapy users in the varenicline and placebo groups from weeks 2 to 52, verified.

In chronic haemorrhage a) several pigmented macrophages fill the alveoli with dense fibrosis of the interstitium; b) the haemosiderin pigment in macrophages.

Conceptual framework of the interaction between environmental exposure including smoking, alpha-1 antitrypsin (AAT) level and/or AAT genotype, other genetic.

Flowchart showing the requirement for starting, documenting and evaluating the effect on quality of life (QoL) of interdisciplinary best supportive care.

Latest trends on smoking in England from the Smoking Toolkit Study

Timeline of approval of therapies for pulmonary arterial hypertension.

Representative photomicrograph of small airways abnormalities in a subject with chronic obstructive pulmonary disease. Representative photomicrograph of.

Kaplan–Meier analysis of survival over 2 years of treatment with riociguat in the CHEST-2 study [54]. Kaplan–Meier analysis of survival over 2 years of.

Smoking cessation rate as point prevalence quit rate from year 1 to 5 in the Lung Health Study with 5,587 chronic obstructive pulmonary disease patients.

Sensitivity analysis describing the features of the lymphatic control on pleural liquid volume. Sensitivity analysis describing the features of the lymphatic.

Patterns of p53 mutations according to smoking habits in a) all lung cancers minus nonsmokers (n = 1,289), b) smokers with lung cancer (n = 419), c) nonsmokers.

Probability of death as a function of the number of months after randomisation in the National Emphysema Treatment Trial comparing medical therapy (––––)

A) Healthcare utilisation, b) short form (SF)-12 scores and c) work productivity and activity impairment in patients with asthma (▓) and diabetes (▪) in.

Nonspecific interstitial pneumonia fibrosing pattern in a case of connective tissue disease. a) The alveolar walls are thickened by interstitial fibrosis.

Reverse remodelling of left and right cavities under specific therapy in a patient with severe idiopathic pulmonary arterial hypertension. a) Before specific.

Prevalence of chronic bronchitis in relation to active smoking, stratified by age. □: nonsmokers; ▒: 1–10 cigarettes per day; ░: 11–20 cigarettes per day;

Diagnostic imaging of distal chronic thromboembolic pulmonary hypertension lesions. a) Ventilation/perfusion scintigraphy. b) Conventional pulmonary angiography.

3-year survival of lung cancer patients in the general population and in those with a prior diagnosis of chronic obstructive pulmonary disease (COPD).

Multimodal management of a central airway obstruction by a squamous cell carcinoma using laser and temporary carinal stent placement, followed by radiation.

Positron emission tomography scan in the axial plane performed in June 2007 showing intense and homogeneous increased uptake of 18-fluorodeoxyglucose within.

Profile of Pseudomonas aeruginosa resistance by country and antibiotic

A summary of the pathogenesis, pathophysiology and clinical implications of the pulmonary vascular and cardiac abnormalities in interstitial lung disease.

a) Central sleep apnoea.

Time to disease progression or death in a) the whole Bosentan Use in Interstitial Lung Disease (BUILD)-1 study population and b) the subpopulation with.

The projected numbers of tobacco-related deaths between 2000–2035 in millions for a) the world and b) medium- and low-income countries (top) and high-income.

Forest plot comparison of mucolytics versus placebo for the number of exacerbations per patient per month. Forest plot comparison of mucolytics versus.

a) The Spiration (Spiration, Inc. , Redmond, WA, USA) device

Effect of omalizumab on change from baseline (B) in a) total asthma symptom score, b) total rhinitis symptom score, and c) combined asthma and rhinitis.

Simplified diagram of the multidisciplinary process to diagnose interstitial lung disease, including a clinician, radiologist, pathologist and also a geneticist:

Morphological subtypes of cyst-related primary lung malignancies

Bronchial thermoplasty procedure

Survival in patients with pulmonary arterial hypertension based on aetiology. •: congenital heart disease; ▪: collagen vascular disease; ▵: HIV-related;

A) Measurement of the right atrial a) area and b) long axis for calculation of right atrial volume. c) Measurement of the left ventricular eccentricity.

Tobacco smoking as a second order schedule of reinforcement.

Oxygen uptake and carbon dioxide removal in the membrane lung

Duration of antibiotic therapy according to clinical pulmonary infection score in a randomised trial of an antibiotic discontinuation policy for clinically.

A) 8-isoprostane levels in exhaled breath condensate in smokers with chronic obstructive pulmonary disease (COPD). *: p

Exposure to intermittent hypoxia after 13 nights led to an increase in sympathetic activity measured by muscle sympathetic nerve activity (MSNA). Exposure.

Impact of dose adjustment in case of adverse drug reaction (ADR; includes dose interruption and/or reduction). a) No dose adjustment and b) dose adjustment.

Percentage of women using snus and/or cigarette smoke during pregnancy based on self-reported time for stopping from those who completed both 18-week and.

A) Conventional pulmonary angiogram, with b) and c) corresponding optical coherence tomography images from a patient with chronic thromboembolic pulmonary.

Kaplan–Meier plots for a) clinical worsening and b) survival in the overall population during the Chronic Thromboembolic Pulmonary Hypertension Soluble.

Overall forest plot from meta-analysis carried out in 11 studies a) assessing the relative risk of adverse events; and subgroup analysis performed on studies.

Representative pressure tracings of a) pulmonary arterial pressure and b) pulmonary arterial wedge pressure (PAWP). Representative pressure tracings of.

Proportion of participants with access to a, b) a radiologist and c, d) a pathologist experienced in interstitial lung diseases to discuss cases of suspected.

Cumulative mortality over 60 months in patients with α1-antitrypsin deficiency and an initial forced expiratory volume in 1 s

A) Annual diagnosed incidence of pulmonary embolism (PE), and b) annual full incidence of chronic thromboembolic pulmonary hypertension (CTEPH) per 100 000.

Decision tree outlining the techniques to be favoured according to the characteristics of the stenosis. Decision tree outlining the techniques to be favoured.

Schematic diagram of the shared subgroups between asthma and chronic obstructive pulmonary disease (COPD). Schematic diagram of the shared subgroups between.

Effect of omalizumab (n = 209) on a) clinically significant and b) severe exacerbation rates, compared with placebo (n = 210). #: adjustment due to a pre-study.

Survival rates in older (>65 years) compared with younger (18–65 years) patients with idiopathic pulmonary arterial hypertension. a) Expected ( )

Progression in the patient’s pulmonary function tests from 2010 to a) Forced vital capacity (FVC); b) total lung capacity (TLC); c) diffusing capacity.

Risk ratio (RR) and number needed to treat (NNT) are time-dependent measures. a) When an intervention is associated with constant relative risk reduction.

Reduction in mean pulmonary vascular resistance (PVR) in 37 subjects following acute sildenafil administration to ongoing bosentan therapy in the COMPASS-1.

Examples of novel short-term drainage devices

Common venovenous extracorporeal membrane oxygen configurations

Evidence-based indications for noninvasive positive-pressure ventilation (NPPV) according to the severity and time of acute respiratory failure (ARF) [18].

24-h blood pressure profile after a, d) one night of intermittent hypoxia (IH) exposure, b, e) 13 nights IH exposure and c, f) 5 days after cessation of.

Pulmonary artery pressure in a) healthy subjects and b) pulmonary hypertension (PH) subjects. Pulmonary artery pressure in a) healthy subjects and b) pulmonary.

Trends of mortality rates in the USA between 1930 and 2000 in males according to cancer site. –––––: stomach; ·······: prostate; –– –– ––: colon and rectum;

Mean change from baseline in percentage predicted forced vital capacity (FVC) in the a) phase III CAPACITY [27] and b) ASCEND [14] studies. #: n=174; ¶:

Drugs that target the prostacyclin pathway and their routes of administration. #: approved only by the US Food and Drug Administration; ¶: approved only.

Baseline New York Heart Association functional class (NYHA FC) predicts survival in patients with pulmonary hypertension using infused epoprostenol therapy.

Flow–volume loops of test breaths and preceding control breaths of a representative chronic obstructive pulmonary disease patient with different degrees.

Flow–volume loops of test breaths and preceding control breaths of three representative chronic obstructive pulmonary disease patients with different degrees.

Real-life pulmonary arterial hypertension (PAH) patient cases to reflect the importance of a collaborative approach to patient engagement. Real-life pulmonary.

High-resolution computed tomography images of smoking-related interstitial lung diseases (ILDs). a) Pulmonary Langerhans cell histiocytosis, b) respiratory.

Cardiac index (CI) changes from baseline following single oral doses of riociguat (Rio) compared with inhaled nitric oxide (NO) in patients with chronic.

Presentation transcript:

The “route to quit” model, which indicates the contribution of different ways of quitting to overall rates of smoking cessation. #: in most cases nicotine replacement therapy was bought over the counter. The “route to quit” model, which indicates the contribution of different ways of quitting to overall rates of smoking cessation. #: in most cases nicotine replacement therapy was bought over the counter. R. West, and J. Stapleton Eur Respir Rev 2008;17:199-204 ©2008 by European Respiratory Society